Caplin Point Labs Q1 Review - Strong Quarter With Steady Margins: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Caplin Point Laboratories Ltd.'s Q1 FY22 revenues grew 25.1% YoY to Rs 300 crore.
Ebitda margins improved 100 basis points YoY to 30.8% due to lower employee expenses.
Subsequently, Ebitda grew 29.3% YoY to Rs 92.6 crore.
Profit after tax grew 29.9% YoY to Rs 70.9 crore.
Caplin Point posted strong Q1 FY22 results and is now foraying into the Indian market with hospital focused injectable products along with extending its U.S. sterile products into other emerging markets.
We continue to be positive about the business and its visibility in medium to long term
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.